Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 1
- Registration Number
- NCT04305236
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT04305834
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 200
- Registration Number
- NCT04293393
- Locations
- 🇪🇸
Hospital Universitario de Burgos, Burgos, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital General Universitario de Alicante, Alicante, Spain
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04256941
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 117
- Registration Number
- NCT04238819
- Locations
- 🇦🇺
Perth Children's Hospital, Perth, Western Australia, Australia
🇯🇵National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇧🇪UZ Gent, Gent, Oost-Vlaanderen, Belgium
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- University of Milano Bicocca
- Target Recruit Count
- 31
- Registration Number
- NCT04227327
- Locations
- 🇮🇹
ASST Lecco, Lecco, Italy
🇮🇹AOU ospedali riuniti Ancona clinica oncologica, Ancona, Italy
🇮🇹ULSS 1 Belluno Ospedale San Martino, Belluno, Italy
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jose Carrillo
- Registration Number
- NCT04220892
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 500
- Registration Number
- NCT04188548
- Locations
- 🇺🇸
Winship Cancer Center Emory University, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 5
- Registration Number
- NCT04165031
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 180
- Registration Number
- NCT04158362
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France
🇫🇷Centre Eugène Marquis, Rennes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.